Dr. Heinz Weidenthaler is the VP of Clinical Strategy for Bavarian Nordic’s Infectious Diseases vaccines. He graduated from Technical University of Munich Medical School in 2000 and completed his MD thesis in immune-oncology. He joined Bavarian Nordic in 2013, initially as Qualified Person for Pharmacovigilance. Previously, he held positions in pharmacovigilance at Novartis and Medigene, being responsible for risk benefit profiles of medicinal products in the respiratory, oncology and immunology indication areas. At BN he has been working on the clinical development of the MVA-BN smallpox vaccine and several recombinant vaccines on the MVA-BN platform, including support throughout the U.S. licensure process of MVA-BN in terms of risk benefit assessment and collaboration with license partners for an Ebola vaccination regimen. Since late 2018, he has been responsible for the overall clinical development pathway of BN’s infectious diseases products, with a main focus on poxvirus diseases and respiratory syncytial virus infections.